Today 07:00

15 June 2026
Surgical Innovations Group plc
("Surgical Innovations", the "Company", or the "Group")
Director appointment
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces the appointment of David Anderson as Chief Financial Officer of the Company with immediate effect.
David is an experienced board director with over 28 years' experience in senior finance roles. He is a chartered accountant and member of the Institute of Chartered Accountants of England and Wales, qualifying with Stoy Hayward (now BDO LLP). From 1998 to 2009 David was an audit partner in their London office before becoming an audit partner with Crowe Clark Whitehill (now Crowe U.K. LLP) from 2010 to 2012. Since then, David has held senior finance roles with Strategic Minerals Plc, Hakkasan Limited and CT Group International Ltd. He currently acts as the CFO and board member of LungLife AI, Inc, and as the non-board CFO and Company Secretary of Verici Dx Plc.
Under the terms of his service contract, David will act as a fractional CFO and join the Board of the Company.
Roy Davis, Chairman of Surgical Innovations said: "We are delighted to welcome David to the Company and the Board. His deep financial expertise and proven track record in listed and high growth businesses makes him an excellent addition to our team. His appointment strengthens our financial leadership as we continue to scale Surgical Innovations and capitalise on the growing demand for minimally invasive surgical solutions."
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:
David Mark Anderson (aged 63) is currently, or has during the past five years, been a director of the following companies:
Current directorships or partnerships | Previous directorships or partnerships |
· Alithia LLP · LungLife AI, Inc
| · Weston Lane Limited
|
Save as set out in this announcement there are no further details to be disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rule for Companies.
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | ||
David Marsh, CEO | Tel: 0113 230 7597 | ||
David Anderson, CFO |
| ||
|
| ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Peter Steel / Graham Hertrich / Anastassiya Eley |
| ||
| |||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Resposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

Further information
Further details of the Group's businesses and products are available on the following websites:
www.sigroupplc.com
www.surginno.com
www.elementalhealthcare.co.uk
To receive regular updates by email, please contact si@walbrookpr.com
Follow the stocks